Mind Medicine (MindMed) Inc. (FRA:MMQ)

Market Cap	1.05B
Revenue (ttm)	n/a
Net Income (ttm)	-143.27M
Shares Out	n/a
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	245
Open	10.66
Previous Close	10.65
Day's Range	10.66 - 10.66
52-Week Range	4.29 - 12.21
Beta	n/a
RSI	55.00
Earnings Date	Mar 5, 2026

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Pharmaceutical Preparations
• CEO: Robert Barrow
• Employees: 74
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MMQ

Financial Performance

Financial numbers in USD